Acurate neo2 TAVR Valve Demonstrate Reduced Paravalvular Leak and Low Permanent Pacemaker Rates
Late-breaking registry data at EuroPCR shows better outcomes than first-generation Acurate neo device.
The Acurate neo2 TAVR valve design enhancements include a 60% larger outer sealing skirt to conform to challenging anatomies. This has minimized paravalvular leaks and imporved clinical outcomes compared to the previous-generation Acurate neo Aortic Valve System.
May 26, 2021 Data presented at hotline and late-breaking trial sessions at the EuroPCR 2021 congress for the updated Boston Scientific Acurate neo2 transcatheter aortic valve replacement (TAVR) system demonstrated positive procedural performance. This including low rates of paravalvular leakage (PVL) and permanent pacemaker implementation (PPI), areas where the first generation Acurate neo heart valve did not perform as well.
The Emory Angle Can Help Eliminate Paravalvular Leak in Transcatheter Mitral Interventions
The angle of catheter entry determines the landing zone for transcatheter mitral valve and can impact implant success
Explaining the Emory TMVR angle. Discordance between mitral annular centerline (yellow lines) and valve orientation imposed by guidewire position within the LV apex (red dashed lines). (B) Valve intrinsic angle (α) is determined by external skirt height. (C) When annular-apical “Emory” angle (red curves) exceeds α (blue curve), annular skirt apposition is not possible, causing PVL (red arrows). (D) The valve is oriented perpendicular to the annual plane using an exteriorized apical guidewire (solid yellow line). Image courtesy of Kendra Grubb, M.D.
Operator
Good afternoon. My name is Katrina, and I will be your conference operator today. At this time, I would like to welcome everyone to Penumbra s First Quarter 2021 Conference Call. [Operator Instructions] Thank you.
I would like to introduce Mr. Stephen Dobson, Investor Relations for Penumbra. Mr. Dobson, you may begin your conference.
Stephen Dobson
Investor Relations
Thank you, operator, and thank you all for joining us on today s call to discuss Penumbra s earnings release for the first quarter of 2021. A copy of the press release and financial tables, which includes the GAAP to non-GAAP reconciliation, can be viewed under the Investors tab on our company website at www.penumbrainc.com. During the course of this conference call, the company will make forward-looking statements pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our financial performance, commercialization, clinical trials, re